Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06073821 · ClinicalTrials.gov registry record · Phase 3
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
A Phase 3 study of CLL, sponsored by BeOne Medicines.
- Active
- Registry status
- Phase 3
- Development phase
- 652
- Enrollment target
- 20
- Study locations
NCT06073821: Active Phase 3 study of CLL, sponsored by BeOne Medicines.
NCT06073821 is a Phase 3 study of CLL that is active but no longer recruiting, run by BeOne Medicines. The registered enrollment target is 652 participants, above the 145-participant average among 8 other CLL trials with a reported enrollment target (350% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06073821, a Phase 3 study of CLL, is active but no longer recruiting, sponsored by BeOne Medicines.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 652 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic lymphocytic leukemia (CLL)
Primary Outcome
PFS is defined as the time from the date of enrollment to the date of first confirmed disease progression or death due to any cause, whichever occurs first, as determined by independent review committee (IRC)
Conditions Studied
Interventions
- DRUG Zanubrutinib
- DRUG Obinutuzumab
- DRUG Venetoclax
- DRUG Sonrotoclax
Study Locations (20)
California
- City of Hope National Medical Center - Duarte
- University of California San Diego (Ucsd) Moores Cancer Center - La Jolla
- Valkyrie Clinical Trials - Los Angeles
- UCLA Department of Medicine Hematologyoncology - Los Angeles
- Chao Family Comprehensive Cancer Center - Orange
- Stanford Medicine - Palo Alto
Florida
- Mount Sinai Comprehensive Cancer Center - Miami Beach
- Moffitt Cancer Center - Tampa
Illinois
- Northwestern University - Chicago
- Illinois Cancercare, Pc - Peoria
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
- Mission Cancer and Blood - Waukee
Alaska
- Alaska Oncology and Hematology, Llc - Anchorage
Colorado
- University of Colorado Cancer Center - Aurora
District of Columbia
- Medstar Georgetown University Hospital - Washington D.C.
Georgia
- Southeastern Regional Medical Center - Newnan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 652 participants |
| Start Date | 2023-11-11 |
| Est. Completion | 2032-12 |
| Phase | Phase 3 |
What the registry record for NCT06073821 still lists
NCT06073821 is an interventional study that assigns participants to a tested intervention. The registered 652 participants enrollment target is mid-sized for trials with a published cap, above the 145-participant average among 8 other CLL trials with a reported enrollment target (350% higher).
The record links to 1 condition, with CLL appearing as the primary indexed condition, and to 4 interventions - of which Zanubrutinib is the first listed.
NCT06073821 names 20 study sites across 12 states, led by California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT06073821 about?
NCT06073821 is a clinical study titled "Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)". The main objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic lymphocytic leukemia (CLL)
What is the current status of trial NCT06073821?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 652 participants. The study started on 2023-11-11. Estimated completion is 2032-12.
What conditions does trial NCT06073821 study?
This clinical trial studies the following conditions: CLL.
What interventions are being tested in trial NCT06073821?
The interventions under investigation include: Zanubrutinib (DRUG), Obinutuzumab (DRUG), Venetoclax (DRUG), Sonrotoclax (DRUG).
Who is sponsoring clinical trial NCT06073821?
This trial is sponsored by BeOne Medicines, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06073821 being conducted?
This trial has 20 study locations across Alaska, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for CLL
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06073821's enrollment target sits among peer trials
652 2nd of 8 the highest of 8 other CLL trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other CLL trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
RECRUITING · Phase 3
-
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
RECRUITING · Phase 3
-
Study of Epcoritamab as a Consolidation Therapy in CLL/SLL
RECRUITING · Phase 2
-
Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
ACTIVE NOT RECRUITING · Phase 1
-
Allogeneic Transplantation From Related Haploidentical Donors
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06287346 · 652 participants
5-Years PMCF Study of Ceramic Dental Implants One-piece Versus Two-piece.
- NCT02934477 · 650 participants
Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis
- NCT04579120 · 650 participants
Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND)
- NCT04875702 · 650 participants · Phase 4
Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI